Reviewing Mymd Pharmaceuticals (NASDAQ:QCLS) & AGM Group (NASDAQ:AGMH)

Mymd Pharmaceuticals (NASDAQ:QCLS) and AGM Group (NASDAQ:AGMH) are both small-cap technology companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Earnings & Valuation

This table compares Mymd Pharmaceuticals and AGM Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	N/A	-$11.63 million	($20.69)	-0.14
AGM Group	$30.56 million	0.12	$560,000.00	N/A	N/A

AGM Group has higher revenue and earnings than Mymd Pharmaceuticals.

Analyst Recommendations

This is a summary of current ratings and target prices for Mymd Pharmaceuticals and AGM Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1	0	0	0	1.00
AGM Group	1	0	0	0	1.00

AGM Group has a consensus target price of $5.77, suggesting a potential upside of 429.36%. Given AGM Group’s higher probable upside, analysts clearly believe AGM Group is more favorable than Mymd Pharmaceuticals.

Institutional & Insider Ownership

9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 0.9% of Mymd Pharmaceuticals shares are owned by company insiders. Comparatively, 34.9% of AGM Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Mymd Pharmaceuticals and AGM Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%
AGM Group	N/A	N/A	N/A

Risk and Volatility

Mymd Pharmaceuticals has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, AGM Group has a beta of 2.49, suggesting that its share price is 149% more volatile than the S&P 500.

Summary

AGM Group beats Mymd Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

About Mymd Pharmaceuticals

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

About AGM Group

AGM Group Holdings Inc. operates as a technology company, engages in the research and development of blockchain-oriented ASIC chip in Singapore, Hong Kong, and China. The company offers MetaTrader 5, a futures trading solution; and foreign exchange trading system that provides services to financial institutions. It also engages in the research and development, manufacture, and sales of technology hardware. In addition, the company sells cryptocurrency mining machine and standardized computing equipment, and technical support plans, as well as delivers fintech software services. AGM Group Holdings Inc. was incorporated in 2015 and is based in Wan Chai, Hong Kong.